Vitamin C (intravenous high-dose) | Cam-Cancer

Vitamin C (intravenous high-dose)

Abstract and key points
  • Vitamin C (L-ascorbate or L-ascorbic acid) has been used in the treatment of cancer patients. Intravenous administration of vitamin C is used to attain pharmacologic concentrations.
  • Anti-cancer activity of high intravenous doses of vitamin C has not been confirmed in clinical trials.
  • There is limited evidence indicating that high-dose intravenous vitamin C might improve the quality of life of patients with advanced cancers.
  • High intravenous doses of vitamin C are generally safe, causing only minor side effects, but are contraindicated in people with renal disease or glucose 6-phosphate dehydrogenase deficiency. They may interact with conventional anti-cancer therapies. 

Physiological concentrations of vitamin C (L-ascorbate or L-ascorbic acid) in the body are controlled through intestinal absorption, tissue accumulation, and renal reabsorption and excretion. Therefore, intravenous administration is used to achieve pharmacologic doses.

In the context of cancer, high-dose intravenous vitamin C (> 0.5 g per kg body weight) is claimed to have several effects: a) cytotoxicity for cancer cells, but not for normal tissue, b) improved quality of life for cancer patients, c) protection of normal tissues from toxicity caused by chemotherapy, and d) reinforcement of the action of radiation and some types of chemotherapy.

A limited number of Phase I clinical trials, including only one controlled trial, confirm the non-toxic character of the treatment, and give some indications that the treatment may improve quality of life, but do not suggest distinct anti-cancer effects. Several case reports argue for a positive effect on survival time, even reporting cancer remission, and improved quality of life.

High-dose vitamin C is essentially non-toxic. Reported side-effects are minor if patients are adequately screened for renal disease and glucose 6-phosphate dehydrogenase deficiency, and when doses are gradually increased with careful monitoring of the patient. Vitamin C might reduce the therapeutic response to some conventional anti-cancer therapies, but may act synergistic with other conventional therapies.

Document history

Most recent update and revision in July 2014 by Luc Geeraert.
Fully updated and revised in October 2012 by Luc Geeraert.
Summary first published in February 2011, authored by Luc Geeraert.

Citation

Luc Geeraert, CAM-Cancer Consortium. Vitamin C (intravenous high-dose) [online document], http://cam-cancer.org/en/high-dose-vitamin-c. July 9, 2014.

What is it?

Description / Names

Vitamin C is also known as L-ascorbic acid or as sodium L-ascorbate.

Ingredients / Components

The richest natural sources of vitamin C are fruits and vegetables, and a balanced diet usually meets the daily requirements. Vitamin C is sold as a nutritional supplement in a variety of forms.

Application and dosage

Vitamin C can be administered via several routes including orally. This article only discusses the intravenous administration of high doses of vitamin C (> 0.5 g per kg body weight).

Phase I dose-finding studies in cancer patients recommend the use of 1.5 g to 2 g intravenous vitamin C per kg body weight three to four times per week1,2. In further clinical research it is advised to start treatment with a lower dose, and, if no adverse events are observed, to gradually increase doses to their final level1,3.

Ascorbic acid solutions for clinical infusion might be unstable over time4-6.

There is no consistent information available as to which clinical dose would be needed to yield an anti-cancer effect7. The above-mentioned dose of 1.5 g per kg body weight was only found to be safe and to be capable to achieve plasma ascorbic acid concentrations of more than 10 mM for several hours in patients with normal renal function1.

History / Claims of efficacy

Vitamin C was isolated by Szent-Györgyi in 19288. The vitamin plays a key role in several biological functions including the biosynthesis of collagen. It is a major water-soluble reducing agent and anti-oxidant, quenching potentially damaging free radicals resulting from metabolic respiration. Acute lack of vitamin C leads to scurvy, a disease marked by connective tissue damage and blood vessel fragility eventually resulting in death9.

Soon after its isolation, methods for vitamin C synthesis were developed and the molecule became widely available. Over the years, a wealth of case reports, anecdotal accounts and pilot studies, all reporting some degree of clinical benefit conferred by supplemental vitamin C in cancer, were published10. Two controlled retrospective studies (using 10 g vitamin C per day, intravenous and oral) by Cameron and Pauling further substantiated these claims11,12. As the latter studies lacked randomization and were retrospective, the US National Cancer Institute (NCI) sponsored two randomized, placebo-controlled, double-blind trials to evaluate the effect of high-dose vitamin C on symptoms and survival of patients with advanced cancer13,14; but Creagan and Moertel, who used 10 g oral (not intravenous) vitamin C per day, did not find a therapeutic benefit in the treatment of cancer. Hence, the use of vitamin C in cancer therapy was abandoned by mainstream oncologists in the 1980s15,16.

In the late 1990s, it was found that vitamin C concentrations in plasma and tissues were tightly controlled through intestinal absorption, tissue accumulation, and renal reabsorption and excretion17-20. As a result, it was impossible to increase plasma and tissue concentrations once oral intake of vitamin C exceeded 200 mg per day. However, intravenous administration bypassed this tight control until equilibrium was restored through renal excretion. In healthy volunteers, oral administration of the maximum tolerated dose of 3 g every 4 hours resulted in peak plasma concentrations of 0.22 mM, while an intravenous vitamin C dose of 50 g produced a peak plasma concentration of 13.4 mM21. Comparable results were found in cancer patients1,22,23.

Hence, the route of administration is critical in achieving pharmacologic concentrations of vitamin C, urging the reevaluation of vitamin C in cancer treatment9,24.

Mechanisms of action / Alleged indications

At the normal low physiological concentrations (0.1 mM), vitamin C is an anti-oxidant that inactivates reactive oxygen species25. However, at high pharmacologic concentrations (up to 20 mM) it was found to become a pro-oxidant generating oxidative species, i.e. extracellular hydrogen peroxide, which is lethal to cancer cells26,27. Normal cells were unaffected by both concentrations of vitamin C. In vitro findings were confirmed in rats and mice, where virtually the same cancer-killing hydrogen peroxide concentrations were found in extracellular fluid, but not in blood, after intravenous administration of high-dose vitamin C; oral doses did not result in generation of hydrogen peroxide28-30. It was proposed that extracellular hydrogen peroxide diffuses into cancer cells and mediates toxicity by ATP depletion, thereby causing cell death. Moreover, hydrogen peroxide toxicity compromises membranes, glucose metabolism, and DNA integrity. In normal cells hydrogen peroxide is readily neutralized by antioxidant enzymes like catalase, glutathione peroxidase, and superoxide dismutase, while levels of these antioxidant enzymes are low or imbalanced in most human cancers31.

Daily high-dose intravenous vitamin C significantly decreased the volume of tumours in mice by 41-53% for diverse aggressive cancer types29. Inhibition of tumour growth was also found in other mouse models of human cancers and in human cancer cell lines9,30,32-34.

Prevalence of use / providers

Although use of high-dose intravenous vitamin C was abandoned by mainstream oncologists, the compound is in wide use by complementary and alternative medicine practitioners35.

Legal issues

None.

Cost and expenditure

Vitamin C infusions, to be applied by a medical practitioner, are widely available at moderate cost (around $150.00 per infusion in a clinic).

Does it work?

Recent findings on the mechanism of action and pharmacokinetics of high-dose intravenous vitamin C triggered a renewed interest in its application as an anti-cancer agent. Therefore, several Phase I clinical trials were initiated and the results of one controlled and six uncontrolled trials have been published. Also, eight case studies and five retrospective studies have been reported. Several clinical trials are underway36.

While the case series and retrospective studies gave some indications for efficacy, the published clinical trials did not indicate tumour response. Overall, evidence for the non-toxic character of intravenous high-dose vitamin C, limited evidence for improved quality of life, and some suggestion of synergism with certain conventional therapy was offered.

Study details can be found in Table 1.

Controlled clinical trials

Only one controlled clinical trial has been published. In this Phase I/IIa randomized controlled clinical trial, Ma et al. randomized 27 patients with newly diagnosed stage III/IV ovarian cancer to receive either conventional paclitaxel/carboplatin therapy alone (control group), or combined with intravenous vitamin C (treatment group)37. Addition of intravenous high-dose vitamin C was found to reduce toxicities associated with chemotherapy.

Retrospective studies

Cameron et al. performed three controlled retrospective studies comparing terminal cancer patients receiving vitamin C with historical control patients that had not received vitamin C, and found increased survival times in the vitamin-C-treated groups11,12,50. The study designs were criticized as they were not randomized nor placebo controlled. Moreover, some patients were treated with oral vitamin C, the treatment period with intravenous vitamin C was only about 10 days, and the doses were rather low.

Vollbracht et al. evaluated intravenous vitamin C administration in the first postoperative year of women with breast cancer, in an epidemiological retrospective cohort study, and found that vitamin C resulted in a significant reduction of complaints induced by the disease and chemo- or radiotherapy. Vitamin C was well-tolerated and had no effect on tumour status after 6 or 12 months51.

Uncontrolled clinical trials

Intravenous vitamin C was well-tolerated in a pilot clinical study in 24 late-stage terminal cancer patients, and one patient had stabilized disease during the trial38. Noteworthy, applied doses of vitamin C were low.Several aspects of health-related quality of life were improved after administration of intravenous high-dose vitamin C to 39 terminal cancer patients: i.e., significantly higher scores for physical, role, emotional, and cognitive function, and significantly lower scores for fatigue, nausea/vomiting, pain, and appetite loss39.

In a dose-finding Phase I and pharmacokinetics study in 24 patients with advanced cancer or hematologic malignancy refractory to standard therapy, high-dose intravenous vitamin C was found to be safe and free of important toxicity. Patients receiving 0.6 g or more of vitamin C per kg body weight maintained physical quality of life throughout the trial. No patient experienced an objective anti-cancer response1.

The combination of intravenous vitamin C with standard treatment of gemcitabine and erlotinib was tested in an open-label, dose-escalating Phase I trial in 14 patients with metastatic pancreatic cancer40. Nine subjects completed the study of which seven patients experienced stable disease. No increased toxicity was revealed with the addition of vitamin C to gemcitabine and erlotinib.

In a Phase I dose-escalation trial in 17 patients with advanced solid tumours not responding to standard therapy, pharmacokinetics of high-dose intravenous vitamin C were determined2. Vitamin C was generally well tolerated and no objective antitumour responses were observed. The authors recommend a dose of 70 to 80 g/m2 (i.e., around 2 g per kg body weight) for future studies.

In a Phase I clinical trial in nine patients with biopsy-proven stage IV pancreatic adenocarcinoma, the concurrent administration of high-dose intravenous vitamin C with gemcitabine was well-tolerated and a suggestion of improved efficacy by vitamin C addition was found41.

Analysis of a database from 45 patients with different cancers treated with high-dose intravenous vitamin C by Mikirova et al. taught that this treatment affected levels of C-reactive protein and pro-inflammation cytokines, supporting the hypothesis that inflammation in cancer patients may be reduced by high-dose intravenous vitamin C52.

Case series/studies

Several case reports on the treatment of advanced cancer patients with high-dose intravenous vitamin C have been published42-49. Vitamin C infusions were either used as sole treatment or combined with conventional therapy. Overall, the results indicated lack of toxicity. Also, in several cases tumour regression or even complete remission was observed.

Noteworthy, for all the successful case reports, alternative explanations for cancer remission are possible, e.g. spontaneous remission or remission due to the therapy received before intravenous vitamin C was initiated. Moreover, a general weakness of case reports is that they omit the number of patients having received high-dose intravenous vitamin C without any effect.

Is it safe?

Adverse events

Vitamin C itself is essentially non-toxic. In general, adverse events after high-dose intravenous vitamin C were mild, and consistent with side effects occurring due to rapid infusion of any high-osmolarity solution, and were preventable by drinking fluids before and during the infusion1,35,38.

Contraindications

Patients with glucose 6-phosphate dehydrogenase deficiency were found to be at risk to experience haemolysis (breakdown of red blood cells) following administration of high doses of vitamin C53,54. Therefore patients should be screened for this metabolic deficiency before initiation of therapy.

Oxalic acid is an end product of metabolic oxidation of vitamin C. Oxalate nephropathy has been reported after administration of intravenous vitamin C in subjects with renal dysfunction55-57. However, in people with normal renal function, the risk of oxalate crystallization in the kidney was not increased58. Therefore, high-dose intravenous vitamin C is contraindicated in people with renal dysfunction, and a history of kidney stones should be reviewed.

Another concern is life-threatening bleeding (haemorrhage) and rapid necrosis of tumours59. Authors therefore advised gradual increase of intravenous vitamin C whilst monitoring the patient.

Interactions

As vitamin C at physiological concentrations has antioxidant properties, it is conceivable that it may attenuate the anti-cancer activity of therapies generating increased reactive oxygen species, e.g. radiation and some chemotherapeutics.

Several studies on interactions of vitamin C and anti-cancer therapies have been performed, both in vitro and in vivo36-37,60-68. Vitamin C was found to reinforce the action of radiation and several chemotherapeutics, while it has no influence or even diminishes the effects of other chemotherapeutics. In this respect, the results of Heaney et al. are worth mentioning69. When comparing the therapeutic efficacy of a range of anticancer agents in cell lines and tumour-bearing mice with and without pretreatment with dehydroascorbic acid (the oxidized form of vitamin C), it was found that the latter caused a dose-dependent reduction of cytotoxicity; however, later studies questioned the relevance of these findings when using pharmacological concentrations of vitamin C63. Also, several studies showed that vitamin C could abrogate the effects of bortezomib when taken simultaneously70.

In conclusion, negative interactions may occur when adding vitamin C to conventional anti-cancer therapy, making the conventional therapy less potent. 

References
  1. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH Jr. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann. Oncol. 2008 November;19(11):1969-74.
  2. Stephenson CM, Levin RD, Spector T, Lis CG. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol. 2013 Jul;72(1):139-146.
  3. Riordan HD, Hunninghake RB, Riordan NH, Jackson JJ, Meng X, Taylor P, Casciari JJ, González MJ, Miranda-Massari JR, Mora EM, Rosario N, Rivera A. Intravenous ascorbic acid: protocol for its application and use. P R Health Sci. J. 2003 September;22(3):287-90.
  4. Allwood MC, Kearney MC. Compatibility and stability of additives in parenteral nutrition admixtures. Nutrition. 1998 September;14(9):697-706.
  5. Dupertuis YM, Morch A, Fathi M, Sierro C, Genton L, Kyle UG, Pichard C. Physical characteristics of total parenteral nutrition bags significantly affect the stability of vitamins C and B1: a controlled prospective study. JPEN J. Parenter. Enteral. Nutr. 2002 September-October;26(5):310-316.
  6. Lavoie JC, Chessex P, Rouleau T, Migneault D, Comte B. Light-induced byproducts of vitamin C in multivitamin solutions. Clin. Chem. 2004 January;50(1):135-140.
  7. Cabanillas F. Vitamin C and cancer: what can we conclude - 1,609 patients and 33 years later? P R Health Sci. J. 2010 September;29(3):215-217.
  8. Szent-Györgyi, A. Observations on the function of peroxidase systems and the chemistry or the adrenal cortex: description of a new carbohydrate derivative. Biochem. J. 1928;22:1387-1409.
  9. Du J, Cullen JJ, Buettner GR. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim. Biophys. Acta. 2012 Dec;1826(2):443-457.
  10. Cameron E, Pauling L, Leibovitz B. Ascorbic acid and cancer: a review. Cancer Research. 1979 March;39(3):663-681.
  11. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc. Natl. Acad. Sci. USA. 1976;73:3685-3689.
  12. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc. Natl. Acad. Sci. USA. 1978;75:4538-4542.
  13. Creagan ET, Moertel CG, O’Fallon JR, Schutt AJ, O’Connel MJ, Rubin J, Frytak S. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. New Engl. J. Med. 1979 September;301(13):687-690.
  14. Moertel CG, Fleming TR, Creagan ET, Rubin J, O’Connel MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. New Engl. J. Med. 1985 January;312(3):137-141.
  15. Wittes RE. Vitamin C and cancer. New Engl. J. Med. 1985 January;312(3):178-179.
  16. Golde DW. Vitamin C in cancer. Integr. Cancer Ther. 2003 June;2(2):158-159.
  17. Levine M, Espey MG, Chen Q. Losing and finding a way at C: new promise for pharmacologic ascorbate in cancer treatment. Free Rad. Biol. Med. 2009 July;47(1):27-29.
  18. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, Park JB, Lazarev A, Graumlich JF, King J, Cantilena LR. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc. Natl. Acad. Sci. USA. 1996 April;93:3704-3709.
  19. Levine M, Wang Y, Padayatti SJ, Morrow J. A new recommended dietary allowance of vitamin C for healthy young women. Proc. Natl. Acad. Sci. USA. 2001 August;98(17):9842-9846.
  20. Graumlich JF, Ludden TM, Conry-Cantilena C, Cantilena Jr LR, Wang Y, Levine M. Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. Pharm. Res. 1997 September;14(9):1133-1139.
  21. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, Levine M. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann. Intern. Med. 2004 April;140(7):533-537.
  22. Casciari JJ, Riordan NH, Schmidt TL, Meng XL, Jackson JA, Riordan HD. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. Br. J. Cancer. 2001 June;84(11):1544-50.
  23. Duconge J, Miranda-Massari JR, González MJ, Taylor PR, Riordan HD, Riordan NH, Casciari JJ, Alliston K. Vitamin C pharmacokinetics after continuous infusion in a patient with prostate cancer. Ann. Pharmacother. 2007 June;41(6):1082-1083.
  24. Padayatty SJ, Levine M. Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J. Am. Coll. Nutr. 2000 August;19(4):423-425.
  25. Carr A, Frei B. Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J. 1999;13:1007-1024.
  26. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc. Natl. Acad. Sci. USA. 2005 September;102(38):13604-13609.
  27. Frei B, Lawson S. Vitamin C and cancer revisited. Proc. Natl. Acad. Sci. USA. 2008 August;105(32):11037-11038.
  28. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, Choyke PL, Pooput C, Kirk KL, Buettner GR, Levine M. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc. Natl. Acad. Sci. USA. 2007 May;104(21):8749-8754.
  29. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc. Natl. Acad. Sci. USA. 2008 August;105(32):11105-11109.
  30. Verrax J, Calderon PB. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic. Biol. Med. 2009 July;47(1):32-40.
  31. Oberley TD, Oberley LW. Antioxidant enzyme levels in cancer. Histol. Histopathol. 1997 April;12(2):525-535.
  32. Pollard HB, Levine MA, Eidelman O, Pollard M. Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo. 2010 May-June;24(3):249-255.
  33. Chen P, Yu J, Chalmers B, Drisko J, Yang J, Li B, Chen Q. Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy. Anticancer Drugs. 2012 April;23(4):437-444.
  34. Mamede AC, Pires AS, Abrantes AM, Tavares SD, Gonçalves AC, Casalta-Lopes JE, Sarmento-Ribeiro AB, Maia JM, Botelho MF. Cytotoxicity of ascorbic acid in a human colorectal adenocarcinoma cell line (WiDr): in vitro and in vivo studies. Nutr Cancer. 2012;64(7):1049-57.
  35. Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One. 2010 July 7;5(7):e11414.
  36. Wilson MK, Baguley BC, Wall C, Jameson MB, Findlay MP. Review of high-dose intravenous vitamin C as an anticancer agent. Asia Pac J Clin Oncol. 2014 Mar;10(1):22-37.
  37. Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014 Feb 5;6(222):222ra18.
  38. Riordan HD, Casciari JJ, González MJ, Riordan NH, Miranda-Massari JR, Taylor P, Jackson JA. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci. J. 2005;24(4):269-276.
  39. Yeom CH, Jung GC, Song KJ. Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J. Korean Med. Sci. 2007 February;22(1):7-11.
  40. Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794.
  41. Welsh JL, Wagner BA, van't Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, Yee NS, Bodeker KL, Du J, Roberts LJ 2nd, Drisko J, Levine M, Buettner GR, Cullen JJ. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013 Mar;71(3):765-775.
  42. Cameron E, Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem. Biol. Interact. 1974;9:285-315.
  43. Riordan H, Jackson J, Schultz M. Case Study: High Dose intravenous Vitamin C in the Treatment of a Patient with Adrenocarcinoma of the Kidney. J. Orthomol. Med. 1990;5:5-7.
  44. Jackson JA, Riordan HD, Hunninghake RE, Riordan N. High dose intravenous vitamin C and long time survival of a patient with cancer of head of the pancreas. J. Orthomol. Med. 1995;10:87-88.
  45. Riordan N, Jackson J, Riordan HD. Intravenous vitamin C in a terminal cancer patient. J. Orthomol. Med. 1996;11:80-82.
  46. Riordan HD, Jackson JA, Riordan NH, Schultz M. High-dose intravenous vitamin C in the treatment of a patient with renal cell carcinoma of the kidney. J. Orthomol. Med. 1998;13:72-73.
  47. Riordan NH, Riordan HD, Casciari, JJ. Clinical and experimental experiences with intravenous vitamin C. J. Orthomolec. Med. 2000;15(4):201-213.
  48. Drisko JA, Chapman J, Hunter VJ. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J. Am. Coll. Nutr. 2003 April;22(2):118-123.
  49. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ. 2006 March;174(7):937-942.
  50. Cameron E, Campbell A. Innovation vs. quality control: an 'unpublishable' clinical trial of supplemental ascorbate in incurable cancer. Med. Hypotheses. 1991 November;36(3):185-189.
  51. Vollbracht C, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo. 2011 November-December;25(6):983-990.
  52. Mikirova N, Casciari J, Rogers A, Taylor P. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med. 2012 Sep 11;10:189.
  53. Campbell GD Jr, Steinberg MH, Bower JD. Letter: Ascorbic acid-induced hemolysis in G-6-PD deficiency. Ann. Intern. Med. 1975 June;82(6):810.
  54. Rees DC, Kelsey H, Richards JD. Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ. 1993 March;306(6881):841-842.
  55. McAllister CJ, Scowden EB, Dewberry FL, Richman A. Renal failure secondary to massive infusion of vitamin C. JAMA. 1984 October;252(13):1684.
  56. Lawton JM, Conway LT, Crosson JT, Smith CL, Abraham PA. Acute oxalate nephropathy after massive ascorbic acid administration. Arch. Intern. Med. 1985 May;145(5):950-951.
  57. Wong K, Thomson C, Bailey RR, McDiarmid S, Gardner J. Acute oxalate nephropathy after a massive intravenous dose of vitamin C. Aust. N. Z. J. Med. 1994 August;24(4):410-411.
  58. Robitaille L, Mamer OA, Miller WH Jr, Levine M, Assouline S, Melnychuk D, Rousseau C, Hoffer LJ. Oxalic acid excretion after intravenous ascorbic acid administration. Metabolism. 2009 February;58(2):263-269.
  59. Campbell A, Jack T. Acute reactions to mega ascorbic acid therapy in malignant disease. Scott. Med. J. 1979 April;24(2):151-153.
  60. Espey MG, Chen P, Chalmers B, Drisko J, Sun AY, Levine M, Chen Q. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med. 2011 June 1;50(11):1610-1619.
  61. Verrax J, Calderon PB. The controversial place of vitamin C in cancer treatment. Biochem. Pharmacol. 2008 December;76(12):1644-1652.
  62. Lamson DW, Brignall MS. Antioxidants and cancer therapy II: quick reference guide. Altern. Med. Rev. 2000 April;5(2):152-163.
  63. Frömberg A, Gutsch D, Schulze D, Vollbracht C, Weiss G, Czubayko F, Aigner A. Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol. 2011 May;67(5):1157-1166.
  64. Shinozaki K, Hosokawa Y, Hazawa M, Kashiwakura I, Okumura K, Kaku T, Nakayama E. Ascorbic acid enhances radiation-induced apoptosis in an HL60 human leukemia cell line. J Radiat Res. 2011;52(2):229-237.
  65. Herst PM, Broadley KW, Harper JL, McConnell MJ. Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest. Free Radic. Biol. Med. 2012 Apr 15;52(8):1486-1493.
  66. Park JH, Davis KR, Lee G, Jung M, Jung Y, Park J, Yi SY, Lee MA, Lee S, Yeom CH, Kim J. Ascorbic acid alleviates toxicity of paclitaxel without interfering with the anticancer efficacy in mice. Nutr Res. 2012 Nov;32(11):873-83.
  67. Vuyyuri SB, Rinkinen J, Worden E, Shim H, Lee S, Davis KR. Ascorbic acid and a cytostatic inhibitor of glycolysis synergistically induce apoptosis in non-small cell lung cancer cells. PLoS One. 2013 Jun 11;8(6):e67081.
  68. Wei Y, Song J, Chen Q, Xing D. Enhancement of photodynamic antitumour effect with pro-oxidant ascorbate. Lasers Surg Med. 2012 Jan;44(1):69-75.
  69. Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA, O'Connor OA. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res. 2008 October 1;68(19):8031-8038.
  70. Perrone G, Hideshima T, Ikeda H, Okawa Y, Calabrese E, Gorgun G, Santo L, Cirstea D, Raje N, Chauhan D, Baccarani M, Cavo M, Anderson KC. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia. 2009 September;23(9):1679-1686.

CAM Cancer is hosted by NAFKAM

Norway's National Research Center in Complementary and Alternative Medicine

Read more about NAFKAM

Other websites from NAFKAM: